Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MITI-101
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : MindImmune Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Wheeler Bio and MindImmune Therapeutics Sign CDMO Partnership Agreement
Details : Wheeler Bio will provide integrated process development and cGMP drug substance manufacturing services via its ModularCMC™ platform to support the advancement of the MITI-101 program.
Product Name : MITI-101
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
September 17, 2025
Lead Product(s) : MITI-101
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : MindImmune Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement